What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?

Breast Cancer Res Treat. 2019 Aug;177(1):231-232. doi: 10.1007/s10549-019-05275-z. Epub 2019 May 22.

Authors

Roberta Maltoni¹, Sara Bravaccini²

Affiliations

¹ Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy.
² Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy. sara.bravaccini@irst.emr.it.

PMID: 31119566
DOI: 10.1007/s10549-019-05275-z

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / therapeutic use
Breast Neoplasms / diagnosis*
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Breast Neoplasms / surgery
Carcinoma, Lobular / diagnosis*
Carcinoma, Lobular / drug therapy*
Carcinoma, Lobular / pathology
Carcinoma, Lobular / surgery
Chemotherapy, Adjuvant
Female
Humans
Ki-67 Antigen / metabolism
Time Factors

Substances

Antineoplastic Agents
Ki-67 Antigen
MKI67 protein, human